Imagine a world without cancer

BMC Cancer

Ijaz S Jamall^1,15  Scott R Steele⁵  Bruno Zilberstein^1,17  Alexander Knuth^2,23  Yuko Kitagawa⁹  Michel Ducreux⁸  Thomas J Reid^1,10  Nitah Maihle³  Martin Daumer^1,15  Timothy J Wallace⁷  Hans-Ulrich Steinau^1,13  Franco Roviello^2,22  Domenico D’Ugo^2,20  Alfredo Garofalo^1,14  Vic Verwaal^1,12  Grzegorz Wallner^1,18  Wojciech Polkowski^1,18  Tomas Skricka⁴  Khay-Guan Yeoh¹  Toshikazu Ushijima²  Han-Kwang Yang^1,11  Florian Lordick^1,19  Raphael E Pollock^1,16  Richard van Hillegersberg^2,21  Gary Lyman⁶  Björn LDM Brücher⁷ 

[1]Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

[2]Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan

[3]Biochemistry and Molecular Biology, Georgia Regents University, Augusta, GA, USA

[4]Department of Surgery, Masaryk University, Brno, Czech Republic

[5]Department of Surgery, Madigan Army Medical Center, Tacoma, WA, USA

[6]Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA

[7]Bon Secours Cancer Institute, Richmond, VA, USA

[8]Departement of Medicine, Institut Gustave Roussy, Villejuif, Universite Paris-Sud, Le Kremlin, Bicetre, France

[9]Department of Surgery, Keio University, Tokyo, Japan

[10]Regional Cancer Center Memorial Hospital of South Bend, South Bend, IN, USA

[11]Department of Surgery, Seoul National University Hospital, Seoul, Korea

[12]The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

[13]University of Essen, Essen, Germany

[14]Institutio Nazionale Tumori Regina Elena, Roma, Italy

[15]INCORE, International Consortium of Research Excellence of the Theodor- Billroth-Academy®, Richmond, VA, USA

[16]Surgical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

[17]Digestive Surgery Division, Sao Paulo University, San Paulo, Brazil

[18]Surgery, Medical University of Lublin, Lublin, Poland

[19]Medical Oncology, University of Leipzig, Leipzig, Germany

[20]Department of Surgery, Catholic University Rome A, Rome, Italy

[21]Department of Surgery, University Medical Center, Utrecht, The Netherlands

[22]Surgical Oncology, University of Siena, Siena, Italy

[23]National Center for Cancer Care and Research, Doha, Qatar

关键词: Individualized anticancer therapy;    Personalized anticancer therapy;    Cancer classification;    Multimodal therapy;    Carcinogenesis;    Cancer;   

Others  :  858970
DOI  :  10.1186/1471-2407-14-186

 received in 2013-11-07, accepted in 2014-03-07,  发布年份 2014

【 摘 要 】

Background

Since the “War on Cancer” was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type.

Discussion

Only a few types of cancer have been described that are associated with one major signaling pathway. This enabled the initial successful deployment of targeted therapy for such cancers. However, soon after this targeted approach was initiated, it was subverted as cancer cells learned and reacted to the initial treatments, oftentimes rendering the treatment less effective or even completely ineffective. During the past 30 plus years, the cancer classification used had, as its primary aim, the facilitation of communication and the exchange of information amongst those caring for cancer patients with the end goal of establishing a standardized approach for the diagnosis and treatment of cancers. This approach should be modified based on the recent research to affect a change from a service-based to an outcome-based approach. The vision of achieving long-term control and/or eradicating or curing cancer is far from being realized, but not impossible. In order to meet the challenges in getting there, any newly proposed anticancer strategy must integrate a personalized treatment outcome approach. This concept is predicated on tumor- and patient-associated variables, combined with an individualized response assessment strategy for therapy modification as suggested by the patient’s own results. As combined strategies may be outcome-orientated and integrate tumor-, patient- as well as cancer-preventive variables, this approach is likely to result in an optimized anticancer strategy.

Summary

Herein, we introduce such an anticancer strategy for all cancer patients, experts, and organizations: Imagine a World without Cancer.

【 授权许可】

   
2014 Brücher et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Kohane IS, Drazen JM, Campion EW: A Glimpse of the next 100 years in Medicine. N Engl J Med 2012, 367(26):2358-2539.
• [2]Schultz M, Parzinger H, Posdnjakov DV, Chikicheva TA, Schmidt-Schultz TH: Oldest known case of metastasizing prostate carcinoma diagnosed in the skeleton of a 2,700-year-old Scythian King from Arzhan (Siberia, Russia). Int J Cancer 2007, 121(12):2591-2595.
• [3]Cunha F: The Edwin Smith surgical papyrus. Am J Surg 1949, 77(6):793-795.
• [4]Breasted JH: Historical tradition and oriental research. Proc Natl Acad Sci 1924, 10(15):289-294.
• [5]Shimkin MB: Contrary to Nature. Washington D.C.: U.S: Department of Health, Education and Welfare; 1977.
• [6]Novinsky M: Zur Frage ueber die Impfungen der Krebsigen Geschwuelste. Centralbl f d Wissenschaften 1876, 14:790-791.
• [7]Sobin LH, Gospodarowicz MK, Wittekind C: TNM classification of malignant tumors, Volume 7. Oxford: Wiley-Blackwell; 2010.
• [8]Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971, 31(11):1860-1861.
• [9]Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting". J Clin Oncol 1989, 7(11):1630-1636.
• [10]Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F: Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology 2009, 73(5):1087-1091.
• [11]Cohen N, Kravchenko-Balasha N, Klein S, Levitzki A: Heterogeneity of gene expression in murine squamous cell carcinoma development – the same tumour by different means. PLoS ONE 2013, 8(3):e57748.
• [12]Druker BJ: Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002, 21(56):8541-8546.
• [13]Von Bubnoff N, Scheller F, Peschel C, Duyster J: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to DTI571: a prospective study. Lancet 2002, 359(9305):487-491.
• [14]Accelerating Progress Against Cancer: ASCO’s Blueprint for Transforming Clinical and Translational Research http://www.asco.org/sites/default/files/blueprint.pdf webcite
• [15]Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA: Cancer mortality surveillance—United States, 1990–2000. MMWR Surveill Summ 2004, 53:1-108.
• [16]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-13.
• [17]Watson EK, Rose PW, Loftus R, Devane C: Cancer survivorship: the impact on primary care. Br J Gen Pract 2011, 61(592):e763-e765.
• [18]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
• [19]Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004, 10(8):789-799.
• [20]Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A: Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012, 38(6):698-707.
• [21]Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128(4):683-692.
• [22]Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R, Rochlitz C: Amplification of Ski is a prognostic marker in early colorectal cancer. Neoplasia 2004, 6(3):207-212.
• [23]Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, Rochlitz C: SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. Br J Cancer 2002, 87(6):630-634.
• [24]Boulay J-L, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, Rochlitz C: Smad 7 is a prognostic marker in patients with colorectal cancer. Int J Cancer 2003, 104(4):446-449.
• [25]Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J: Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 2013, 31(16):1931-1938.
• [26]Kim JC, Kim SY, Cho DH, Ha YJ, Choi EY, Kim CW, Roh SA, Kim TW, Ju H, Kim YS: Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clin Cancer Res 2011, 17(5):1200-1209.
• [27]Kim JC, Ha YJ, Roh SA, Choi EY, Yoon YS, Kim KP, Hong YS, Kim TW, Cho DH, Kim SY, Kim YS: Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer. Br J Cancer 2013, 108(9):1862-1869.
• [28]Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC: Metabolic phenotyping in clinical and surgical environments. Nature 2012, 491(7424):384-392.
• [29]Dudziec E, Goepe JR, Catto JW: Global epigenetic profiling in bladder carcinoma. Epigenomics 2011, 3(1):34-45.
• [30]Bensinger SJ, Christofk HR: New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol 2012, 23(4):352-361.
• [31]DeBernadinis RJ, Lum JJ, Hatzivassilou G, Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 2008, 7(1):11-20.
• [32]Brücher BLDM, Swisher S, Konigsrainer H, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA: Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol 2009, 16(4):878-886.
• [33]Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG: AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013, 17(1):113-124.
• [34]Yaffee MB: The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment. Sci Signal 2013, 6(269):e13.
• [35]Honda K, Ono M, Shitashige M, Masuda M, Kamita M, Miura N, Yamada T: Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn J Clin Oncol 2013, 43(2):103-109.
• [36]Zhou W, Liotta LA, Petricoin EF: Cancer metabolism: what we can learn from proteomic analysis by mass spectrometry. Cancer Genomics Proteomics 2012, 9(6):373-381.
• [37]Leung F, Diamandis EP, Kulasingam V: From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. Biomark Med 2012, 6(5):613-625.
• [38]Grivennikov SI, Greten FR, Karin M: Immunity, Inflammation, and Cancer. Cell 2010, 140(6):883-899.
• [39]Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118(3):285-296.
• [40]Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431(7007):461-466.
• [41]Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348(3):203-213.
• [42]Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marrogi OL, Freeman SM: Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997, 74(5):492-501.
• [43]Vesalainen S, Lipponen P, Talja M, Syrjanen K: Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994, 30A(12):1797-1803.
• [44]Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H: Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001, 61(13):5132-5136.
• [45]Schumacher K, Haensch W, Roefzaad C, Schlag PM: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001, 61(10):3932-3936.
• [46]Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58(16):3491-3494.
• [47]Halpern AC, Schuchter LM: Prognostic models in melanoma. Semin Oncol 1997, 24(Suppl4):S2-S7.
• [48]Kawalec P, Paszulewic A, Holko P, Pilc A: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta analysis. Arch Med Sci 2012, 8(59):767-775.
• [49]Wilginhof S, Four SD, Vandenbroucke F, Everaert H, Salmon I, Liénard D, Marmol VD, Neyns B: Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013, 36:215-222.
• [50]Yamanaka S: Induced pulripotent stem cells: past, present, and future. Cell Stem Cell 2012, 10(6):678-684.
• [51]Hanna JH, Saha K, Jaenisch R: Pluripotency and cellular programming: facts, hypotheses, unresolved issues. Cell 2010, 143(4):508-525.
• [52]Hulsegge G, Susan H, Picavet J, Nooyens AC, Spijkerman AM, van der Schouw YT, Smit HA, Verschuren WM: Today's adult generations are less healthy than their predecessors: generation shifts in metabolic risk factors: the doetinchem cohort study. Eur J Prev Cardiol 2013. Apr 15 [Epub ahead of print]
• [53]Galway K, Black A, Cantwell M, Cardwell CR, Mills M, Donnelly M: Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients. Cochrane Database Syst Rev 2012., 11CD007064
• [54]Graham J, Ramirez A, Love S, Richards M, Burgess C: Stressful life experiences and risk of relapse of breast cancer: observational cohort study. BMJ 2002, 324(7351):1420.
• [55]Chida Y, Hamer M, Wardle J, Steptoe A: Do stress-related psychosocial factors contribute to cancer incidence and survival? Nature Clinical Practice Oncology 2008, 5(8):466-475.
• [56]Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner NL, Munoz SA, Zijlstra A, Yang X, Sterling JA, Elefteriou F: Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 2012, 10(7):e1001363.
• [57]Balboni MJ, Sullivan A, Amobi A, Phelps AC, Gorman DP, Zollfrank A, Peteet JR, Prigerson HG, Vanderweele TJ, Balboni TA: Why is spiritual care infrequent at the end of life? Spiritual care perceptions among patients, nurses, and physicians and the role of training. J Clin Oncol 2013, 31(4):461-467.
• [58]Shah MA, Kelsen DP: Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw 2010, 8(4):437-447.
• [59]Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347(21):1662-1669.
• [60]Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20.
• [61]Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47(1):207-214.
• [62]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
• [63]James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P: Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999, 91(6):523-528.
• [64]Brücher BLDM, Bilchik A, Nissan A, Avital I, Stojadinovic A: Tumor response criteria: are they appropriate? Future Oncology 2012, 8(8):903-906.
• [65]Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007, 8(9):797-805.
• [66]National Cancer Institute: General cancer prevention information. Website National Cancer Institute 2013. http://www.cancer.gov/cancertopics/prevention webcite
• [67]Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW: Cancer genome landscapes. Science 2013, 339(6127):1546-1558.
• [68]Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70.
• [69]Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118(12):3030-3044.
• [70]Xia JJ, Gulati R, Au M, Gore JL, Lin DW, Etzioni R: Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation observation trial. J Natl Cancer Inst 2013, 105(8):546-550.
• [71]Steevens J, Schouten LJ, Driessen AL: Toenail selenium status and the risk of Barrett's esophagus: the Netherlands Cohort Study. Cancer Causes Control 2010, 21(12):2259-2268.
• [72]Van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA: Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2003, 12(9):866-871.
• [73]Rosenthal E: The .7 Trillion Medical Bill. The New York Times; 2013. http://www.nytimes.com/2013/06/02/health/colonoscopies-explain-why-us-leads-the-world-in-health-expenditures.html?_r=1& webcite